Media Teleconference: FDA Approves Alli(TM) (Orlistat 60 Mg Capsules) Over-the-Counter
Posted on: Thursday, 8 February 2007, 09:01 CST
PITTSBURGH, Feb. 8 /PRNewswire/ --
WHAT: Today, the U.S. Food and Drug Administration (FDA) approved the weight-loss product orlistat 60 mg capsules for over-the-counter (OTC) use in the United States. Marketed under the brand name alli(TM), this is the only FDA-approved weight-loss product soon to be available without a prescription and the first clinically- proven OTC product to be combined with a comprehensive support program. It is for use by overweight adults in conjunction with a reduced-calorie, low-fat diet. Please join us for a teleconference, where you will learn more about alli, a truly unique approach to weight loss that combines a safe and effective product with an innovative, personalized support program. There will also be a question and answer session. WHO: George Quesnelle, President, North America, GlaxoSmithKline Consumer Healthcare Steve Burton, Vice President, Weight Control Division, GlaxoSmithKline Consumer Healthcare Dr. Vidhu Bansal, Pharm. D, Director of Medical Affairs, GlaxoSmithKline Consumer Healthcare Caroline Apovian, MD, Director of the Center for Nutrition and Weight Management, Boston Medical Center One-on-one interviews are available upon request WHY: Consumers spend billions of dollars each year on fad diets, unproven weight-loss miracle pills and potentially unsafe supplements that may not work. Approximately 65 percent of U.S. adults are overweight or obese, according to the National Institutes of Health. Overweight and obesity are associated with an increased risk of developing hypertension, type 2 diabetes and heart disease. WHEN: Thursday, February 8, 2007 10:30 a.m. - 11:30 a.m. ET DIAL-IN: Please use the following dial-in information to participate: Dial-in #: (800) 374-2482 Conference ID #: 8026958[For International Participants, Dial: (706) 679-5684]
Dr. Apovian has provided medical expertise and advice throughout the development of the alli program and has received compensation for her time to do so.
GlaxoSmithKline Consumer Healthcare
CONTACT: Dave Schemelia, HealthSTAR Public Relations, +1-646-722-8819(Office), or +1-609-468-9325 (Cell), for GlaxoSmithKline Consumer Healthcare
Source: PRNewswire
Related Articles
- GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands
- /C O R R E C T I O N -- GlaxoSmithKline Consumer Healthcare/
- GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the World's Smokers with Quit Aids
- Statement From the Consumer Healthcare Products Association on the SAMHSA Findings on Cough Medicine Abuse
- GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDA's Current Two-Class Drug System
- Kaiser Permanente Colorado Offers Its Employees incentaHEALTH Weight Loss and Wellness Program for Fourth Consecutive Year
- FDA Joint Advisory Committee Sets Date to Review GlaxoSmithKline Consumer Healthcare's Proposal for Orlistat 60(Mg) Capsules for Over-the-Counter Use
- GlaxoSmithKline Consumer Healthcare, ADA Foundation Announce Recipients of Grants for Improving Older Adult Access to Oral Care
- GlaxoSmithKline Consumer Healthcare to Promote Benefit of Weight Loss With Xenical(R) (Orlistat) for Preventing Type 2 Diabetes
- GlaxoSmithKline Consumer Healthcare Expands Summer Science Program to 13 Pittsburgh-Area Libraries
 |
 |
User Comments (0)
RSS Feeds